Vimta Labs Q4 FY26: Profit Rs 21.1 cr, Dividend Rs 2

What Vimta Labs reported for Q4 FY26

Vimta Labs Limited reported a higher profit for the March quarter of FY26, supported by growth in its core testing and research services. For Q4 FY26, the company posted total income of Rs 112 crore and profit after tax (PAT) of Rs 21.11 crore.

In the same quarter last year (Q4 FY25), it had reported total income of Rs 96.08 crore and PAT of Rs 18.32 crore. The year-on-year comparison indicates stronger execution through the quarter, alongside steady demand across key service lines.

The company also shared operational commentary through its earnings call, pointing to consistent growth across business segments, a focus on quality and compliance, and expansion plans in biologics contract research and development services.

Quarter-on-quarter momentum and how Q4 compared to Q3

The company’s audited results table shows Q4 FY26 revenue rose 11.5% quarter-on-quarter from Rs 100.46 crore in Q3 FY26. Net profit increased to Rs 21.11 crore in Q4 from Rs 17.59 crore in Q3.

From the management commentary, food testing tends to see a stronger performance in Q4, and the company attributed the quarter’s revenue drivers largely to pre-clinical work and food testing. On exports, the company indicated that exported revenue in Q4 was around 38%.

Full-year FY26 performance versus FY25

For the full year FY26, Vimta Labs reported total income of Rs 463.3 crore, compared with Rs 348.2 crore in FY25. Annual EBITDA stood at Rs 148.9 crore in FY26, versus Rs 126.2 crore in FY25.

PAT for FY26 came in at Rs 77.5 crore, up from Rs 66.8 crore in FY25. The company reported basic EPS of Rs 17.4 for FY26.

Management described FY26 as a year of strong execution and resilience, and said demand remained robust across service lines. It also highlighted industry tailwinds such as tightening quality norms, increasing regulatory scrutiny, and an expanding wellness ecosystem.

Segment commentary: pharma testing remained the largest contributor

Management said pharmaceutical research and testing services remained the largest contributor to revenue, with demand from domestic and international customers. Food testing was also described as showing good momentum.

The company said electronics and electrical testing and environmental testing continued to scale in line with expectations. In earlier quarterly commentary (Q3 and nine months FY26 call), management had also flagged a lag in bookings for clinical work and operational challenges in analytical services that led to some revenue deferrals.

Margins: EBITDA at 37.6% in Q4, 35.8% for FY26

For Q4 FY26, EBITDA was reported at Rs 42.1 crore, compared with Rs 34.7 crore in Q4 FY25. EBITDA margin for the quarter stood at 37.6%.

For the full year, EBITDA margin was reported at 35.8%, which the company said it aims to sustain in a stable and competitive range, while acknowledging potential fluctuations from capacity ramp-ups, maintenance costs, and people investments.

PAT margin stood at 18.9% for Q4 FY26 and 18.6% for FY26.

Balance sheet position: net debt-free with cash around Rs 65 crore

On the balance sheet, the company said it continues to remain net debt-free. It reported cash and cash equivalents, including bank balances, close to Rs 65 crore.

This position can be relevant for investors tracking funding needs for expansion initiatives, given the company’s stated plans to build new capabilities.

Dividend recommendation and chairman reappointment

Following the profit growth, the board recommended a final dividend of Rs 2 per equity share of face value Rs 2 for FY26.

Separately, the board recommended the reappointment of Dr S P Vasireddy as the executive chairman for a period of five years.

Accounting comparability after diagnostics divestment

During the earnings call, the company highlighted that it divested its diagnostics and pathological services business in 2024. It said prior-period figures have been regrouped to ensure a like-to-like comparison with current-quarter results.

This is a key disclosure for readers comparing growth trends across periods, because reported numbers for previous periods may reflect reclassification for comparability.

Biologics contract R&D: entry described as a strategic milestone

Management said FY26 marked a strategic milestone with its entry into biologics contract research and development services. In the Q3 commentary, it also stated that equipment procurement and facility setup were on track, and it was confident of commercialising these services by Q1 of the next fiscal.

The company framed FY27 as a year focused on execution, learning, and building credibility in this area.

Key financial snapshot

What investors typically track from here

The disclosures point investors to a few near-term items: sustainability of margins around the mid-30% EBITDA range, quarterly movement in food testing and pre-clinical demand, and progress on commercialising biologics contract R&D services.

The company has also flagged the importance of quality and compliance, noting it underwent multiple regulatory and customer audits during the year. For FY26, the company paired growth with a dividend recommendation and reiterated its net debt-free position.